Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, July 08, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: ...

The vaccines are intended to be developed for use against Marburg virus and Sudan ebolavirus, two hemorrhagic fevers in the ...

Basilea already secured $29 million to develop its antifungals fosmanogepix and BAL2062, and the Swiss company announced this morning that it has confirmed it will also receive its next tranche of $39 ...

The US Department of Health and Human Services is weighing whether to fund new Marburg and Sudan Ebola virus vaccines even as Secretary Robert F. Kennedy Jr. overhauls the US immunization landscape, ...

The full approval of Spikevax covers children aged six months through 11 years who are at increased risk for severe COVID-19, transitioning the vaccine from emergency use to full licensure.

Soligenix (NASDAQ: SNGX) , a late-stage biopharmaceutical company developing therapies for rare diseases with unmet medical needs, issued a sharehold ...

Salarius also announces continued progress in its planned merger with Decoy Therapeutics Inc. (Decoy). Under the definitive agreement announced on January 13, 2025, Decoy will merge with a wholly ...

The US Government’s Biomedical Advanced Research and Development Authority (BARDA) has made an initial investment of approximately $55 million for rapid development of VIR-2482, the Vir ...

The award from the Biomedical Advanced Research and Development Authority (BARDA) will be used to accelerate the development of pandemic flu vaccines, according to Moderna, and specifically ...

Single doses of 150 milligrams (mg), 300 mg, and 450 mg provided 58%, 61%, and 76% protection from symptomatic flu, ...

The new Western Sydney International Airport is not the only drawcard for the aerotropolis. Bradfield city also contains a ...